{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:56:30Z","timestamp":1792281390658,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cjca.2025.07.027","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T14:46:59Z","timestamp":1760798819000},"page":"1857-1874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Canadian Cardiovascular Society\/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%)"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-1609","authenticated-orcid":false,"given":"Sean","family":"Virani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Aleksova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anique","family":"Ducharme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Foroutan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"McGuinty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Mielniczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O\u2019Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Siatecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Swiggum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky D.","family":"Turgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bains","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabe","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nowell","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Heshka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"McCleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Outbih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia Ming Ching","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2025.07.027_bib1","first-page":"531","article-title":"CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib2","first-page":"1030","article-title":"Canadian Cardiovascular Society-Canadian Heart Failure Society focused clinical practice update of patients with differing heart failure phenotypes","volume":"39","author":"Ducharme","year":"2023","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.28964","article-title":"Trends in mortality after incident hospitalization for heart failure among Medicare beneficiaries","volume":"7","author":"Vohra","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cjca.2025.07.027_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ejhf.3499","article-title":"Long-term clinical outcomes and healthcare resource utilization in male and female patients following hospitalization for heart failure","volume":"27","author":"Averbuch","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib5","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cjco.2022.04.011","article-title":"The state of heart failure care in Canada: minimal improvement in readmissions over time despite an increased number of evidence-based therapies","volume":"4","author":"Poon","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.cjca.2025.07.027_bib6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cjco.2024.11.019","article-title":"Economic burden of heart failure hospitalizations in Canada: a population-based study","volume":"7","author":"Ellis","year":"2024","journal-title":"CJC Open"},{"key":"10.1016\/j.cjca.2025.07.027_bib7","first-page":"1342","article-title":"2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib8","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1093\/eurheartj\/ehad389","article-title":"Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction","volume":"44","author":"Pandey","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.07.027_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib10","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib12","first-page":"159","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O\u2019Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jamacardio.2023.5318","article-title":"Dapagliflozin and mode of death in heart failure with improved ejection fraction: a post hoc analysis of the DELIVER trial","volume":"9","author":"Vardeny","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib14","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.cjca.2025.07.027_bib17","article-title":"Characterising patient preferences for treatment attributes in heart failure with preserved ejection fraction (abstract)","volume":"25","author":"Johnson","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.cjca.2025.07.027_bib18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/eurjhf\/hft071","article-title":"Preferences of heart failure patients in daily clinical practice: quality of life or longevity?","volume":"15","author":"Kraai","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.07.027_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.07.027_bib21","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2024.10","article-title":"Evidence for aldosterone antagonism in heart failure","volume":"10","author":"Sethi","year":"2024","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.cjca.2025.07.027_bib22","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jchf.2024.08.007","article-title":"Mineralocorticoid antagonism in heart failure: established and emerging therapeutic role","volume":"12","author":"Chang","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.07.027_bib25","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib26","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.07.027_bib27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.07.027_bib28","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.07.027_bib30","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ejhf.1575","article-title":"Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study","volume":"21","author":"Kimmoun","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib31","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","article-title":"Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction","volume":"81","author":"Pagnesi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jchf.2024.03.006","article-title":"Cost-effectiveness of medical therapy for heart failure with mildly reduced and preserved ejection fraction","volume":"12","author":"Dixit","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.cjca.2025.07.027_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.cjca.2025.07.027_bib35","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000531217","article-title":"Study on the efficacy of sacubitril\/valsartan in patients with heart failure with preserved ejection fraction undergoing peritoneal dialysis","volume":"148","author":"Sheng","year":"2023","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2025.07.027_bib36","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/CIRCULATIONAHA.120.050398","article-title":"Angiotensin receptor-neprilysin inhibitor therapy for heart failure with preserved ejection fraction improves renal outcomes","volume":"142","author":"Tobe","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.07.027_bib37","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamacardio.2019.4665","article-title":"Initiation of angiotensin-neprilysin inhibition after acute decompensated heart failure: secondary analysis of the open-label extension of the PIONEER-HF trial","volume":"5","author":"DeVore","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0008-6363(00)00101-2","article-title":"Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts","volume":"47","author":"Yamamoto","year":"2000","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2025.07.027_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib42","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib43","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.07.027_bib44","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.07.027_bib45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jchf.2023.07.014","article-title":"Pharmacological treatments in heart failure with mildly reduced and preserved ejection fraction: systematic review and network meta-analysis","volume":"12","author":"Zafeiropoulos","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib46","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/jamacardio.2023.3216","article-title":"Health and economic evaluation of sacubitril-valsartan for heart failure management","volume":"8","author":"Bhatt","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib47","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2022.06.037","article-title":"Sacubitril\/valsartan and frailty in patients with heart failure and preserved ejection fraction","volume":"80","author":"Butt","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2025.07.027_bib49","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2018.01.004","article-title":"Rationale and design of the comParIson Of sacubitril\/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial","volume":"198","author":"Velazquez","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2025.07.027_bib50","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib51","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.jacc.2024.02.035","article-title":"Sacubitril\/valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction","volume":"83","author":"Fo\u00e0","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007901","article-title":"Global differences in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"14","author":"Tromp","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib54","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018799","article-title":"Quantifying the sex-race\/ethnicity-specific burden of obesity on incident diabetes mellitus in the United States, 2001 to 2016: MESA and NHANES","volume":"10","author":"Cameron","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.07.027_bib55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.07.027_bib56","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jchf.2018.08.007","article-title":"Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF","volume":"6","author":"Kitzman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib57","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/eurheartj\/ehaa823","article-title":"Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction","volume":"42","author":"Sorimachi","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.07.027_bib58","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1161\/CIRCULATIONAHA.115.015884","article-title":"Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"132","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2025.07.027_bib59","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jacc.2010.10.042","article-title":"Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort","volume":"57","author":"Russo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2025.07.027_bib60","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","article-title":"Obesity and the risk of new-onset atrial fibrillation","volume":"292","author":"Wang","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2025.07.027_bib61","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/eurheartj\/ehw241","article-title":"Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction","volume":"37","author":"Borlaug","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2025.07.027_bib62","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.032463","article-title":"Potential mediators for treatment effects of novel diabetes medications on cardiovascular and renal outcomes: a meta-regression analysis","volume":"13","author":"Rodriguez-Valadez","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2025.07.027_bib63","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib64","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype","volume":"11","author":"Kosiborod","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib65","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib66","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib67","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.07.027_bib68","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.07.027_bib69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib71","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2025.07.027_bib72","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa060838","article-title":"Feasibility of treating prehypertension with an angiotensin-receptor blocker","volume":"354","author":"Julius","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2025.07.027_bib73","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2025.07.027_bib74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ejhf.29","article-title":"Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved","volume":"16","author":"Rogers","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2025.07.027_bib75","doi-asserted-by":"crossref","first-page":"915","DOI":"10.46747\/cfp.6712915","article-title":"Medication management for heart failure with reduced ejection fraction: clinical pearls for optimizing evidenced-informed therapy","volume":"67","author":"Barry","year":"2021","journal-title":"Can Fam Physician"}],"updated-by":[{"DOI":"10.1016\/j.cjca.2025.12.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000}},{"DOI":"10.1016\/j.cjca.2025.12.030","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000}},{"DOI":"10.1016\/j.cjca.2025.12.001","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000}},{"DOI":"10.1016\/j.cjca.2026.03.026","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000}},{"DOI":"10.1016\/j.cjca.2025.12.030","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}},{"DOI":"10.1016\/j.cjca.2026.03.026","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25006403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X25006403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:09:04Z","timestamp":1780337344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X25006403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0828282X25006403"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2025.07.027","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canadian Cardiovascular Society\/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%)","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2025.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2025.05.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}